TORONTO, ON /ACCESSWIRE/June 28, 2022/ RYA GROUP Inc. (CSE:RYAH) is pleased to announce Jules Gagnon as Assistant Vice President of Investor Relations.
In Mr. Gagnon’s new role, he will be responsible for coordinating the Company’s efforts to communicate and engage with investors, drawing on its network of investors and financial market participants, and directing activities on various social media platforms such as LinkedIn and Twitter.
“Jules brings a unique set of communication skills, understanding of investors and marketing strategies that will be invaluable to the growth of this business,” said CEO David Richards. “It will connect us to valuable capital markets, build relationships with new long-term investors and improve investor relations generally.”
“I am delighted to be part of the RYAH Group at such a crucial time for the business. Until now, RYAH has been primarily recognized as a medical device and software company, through various partnerships with clinical groups. In the future, not only will the company continue to help the scientific community make herbal medical breakthroughs, RYAH will become a global lifestyle brand that will provide any individual with wellness solutions to meet their needs. My goal is to help the investment community understand the company’s revised strategic approach, as well as our medium and long-term trajectory to profitable growth.”
Compensation for the role of Investor Relations AVP includes the issuance of 1,000,000 stock options. Under securities regulations, options to Jules Gagnon will vest over 12 months, 25% at the end of each quarter following his hiring. The option exercise price will be $0.075 per share.
RYAH wishes to announce that it has completed a portion of its proposed private placement of subordinate voting share units at a price of $0.03 per share unit. The Company raised $255,000 through the issuance of 8,500,000 share units. Each subordinate voting share unit consists of one (1) subordinate voting share and one (1) warrant. Each warrant entitles its holder to acquire one additional share at a price of five cents ($0.05) per share for a period of two (2) years from the date of issue. The placement was made with accredited investors. The proceeds of the placement must be used for the Company’s working capital. The Company is continuing its efforts to raise additional capital in connection with this placement.
About RYAH Group Inc.:
RYAH is a big data and technology company that enables valuable AI-powered predictive analytics of the efficacy of herbal medicines and other nutraceuticals delivered through its line of innovative IoT-connected medical devices, including inhalers, patches and pens. RYAH’s robust big data platform, the only one of its kind in this space, aggregates and analyzes HIPAA-compliant patient data, helping physicians and patients to personalize treatments, monitor dosages, and better predict and monitor results. Beyond specific medical uses, RYAH supports the use of a variety of nutraceuticals by users for wellness purposes, including personal enjoyment – i.e. recreational use. The collection and analysis of objective and subjective usage data, as well as data derived from natural language processing from various scientific and other relevant publications, will yield invaluable insights for a wide variety of stakeholders, starting with the users themselves and extending to clinicians, medical scientists, insurers, dispensaries, licensed producers, producers, pharmaceutical producers, etc. Through the above, a relentless focus on innovation and a track record of developing win-win collaborative partnerships within relevant industries, RYAH is continuously building a unique and highly valuable intellectual property portfolio and assets of big data ready to be monetized.
AI: Artificial Intelligence
IoT: Internet of Things
HIPAA: Health Insurance Portability and Accountability Act
IP: intellectual property
R&D: Research and Development
NFT: non-fungible token
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “have the “intent to”, “expect”, “ongoing” and other similar expressions that constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, our expectations regarding market acceptance of our products, our strategy for developing new products and improving the capabilities of existing products, our research and development strategy, the impact of competitive products and pricing, new product development and uncertainties related to the regulatory approval process. These statements reflect the Company’s current views with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time to time in the Company’s current filings with regulatory authorities. securities regulations, which documents may be viewed at www.sedar.com. Actual results, events and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by applicable securities laws.
For more information, contact:
Dr. David R. Richards, CEO: [email protected] +1.703.453.7170
Mr. Jules Gagnon, AVP, Investor Relations: [email protected] +1.514.781.7030
THE SOURCE: RYAH Medtech Inc.
See the source version on accesswire.com: